CytomX Therapeutics

CytomX presented early phase‑I data for Varseta‑M in advanced colorectal cancer at the Morgan Stanley Healthcare Conference, showing response rates of 20–30% and an estimated median PFS of 6–7 months. The main adverse event was grade‑3 diarrhea; prophylaxis and dose adjustments reduced severe cases from about 30% to around 10%. The company has pro forma roughly $367 million in cash (runway to at least H2 2028) and is simultaneously advancing a masked interferon‑alfa‑2b program for PD‑1‑refractory melanoma, with first data expected in H1 2025. Next steps include dose selection and regulatory study design under Project Optimus, as well as additional combinations and indication expansions. » Más en de.investing.com

CytomX presented positive efficacy data for Varseta‑M in metastatic colorectal cancer at a health conference (ORR 20–30% vs. 1–2% with standard therapy) and emphasized safety‑management improvements, with grade‑3 diarrhea in optimization cohorts falling to about 10%. The company received a $37 million upfront payment from Regeneron, plans a comprehensive data update by the end of 2024, and intends to discuss regulatory strategy with the FDA in 2024. A first registration‑relevant study could start in the first half of 2025; the second lead program, CX‑801, is also expected to deliver initial data in H1 2025. » Más en de.investing.com

CytomX presented its Probody portfolio at the Wells‑Fargo conference with Varseta‑M as the only known EpCAM‑targeting ADC in development, showing encouraging phase‑1 data in metastatic colorectal cancer and an FDA fast‑track designation. The company has more than $350 million in liquid assets, supported by an expanded collaboration with Regeneron. The second program, CX‑801 (masked interferon alfa‑2b), has shown initial biomarker activity in melanomas. Key milestones include additional phase‑1 data by the end of 2024, combination data with bevacizumab in H1 2025, and the planned start of a registrational study for Varseta‑M in H1 2027. » Más en de.investing.com